The issue of the company amounts to 500,000 leva (255,650 euros), divided in as many shares with 1 leva par value each and represents the registered capital of the company.
The issue and the company will be entered in FSC's public register.
Major shareholders in Unipharma include Ognyan Donev (38.37%,), Ventsislav Stoev (19.25%) and Ognyan Palaveev (12.89%) who is also the executive director of the company.
Unipharm's core activity is the production of high quality drugs, R&D of new technologies for the production of drugs, as well as distribution of drugs.
The company manufactures own products, as well as products under an assignment contract from its main partner Sopharma.